Lornoxicam in the treatment of acute and chronic musculoskeletal pain

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly used type of drugs in the world and are prescribed for a wide range of indications, including osteoarthritis, rheumatoid arthritis, other diseases of the musculoskeletal system and soft tissues, as well as for the relief of postoperative pain. It is well known that the use of NSAIDs is associated with the risk of gastrointestinal (GIT), cardiovascular (CVS) and kidneys complications. Lornoxicam belongs to the NSAIDs of the oxicam class and is a balanced inhibitor of both cyclooxygenase (COX) isoforms – COX1 and COX2 – and differs from other oxicams in its rapid onset of action, high elimination rate. The drug is characterized by a pronounced analgesic effect and a favorable safety profile both in relation to the gastrointestinal tract and cardiovascular system, does not require dose adjustment in patients over 65 years of age.